Rafferty Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-183,293
| Closed | -$7.49M | – | 1203 |
|
|
2024
Q2 | $7.49M | Sell |
183,293
-39,021
| -18% | -$1.6M | 0.03% | 329 |
|
|
2024
Q1 | $9.4M | Buy |
222,314
+80,837
| +57% | +$3.42M | 0.04% | 285 |
|
|
2023
Q4 | $6M | Sell |
141,477
-57,516
| -29% | -$2.44M | 0.03% | 400 |
|
|
2023
Q3 | $4.34M | Buy |
198,993
+22,288
| +13% | +$487K | 0.03% | 419 |
|
|
2023
Q2 | $5.62M | Sell |
176,705
-33,480
| -16% | -$1.06M | 0.03% | 382 |
|
|
2023
Q1 | $5.13M | Sell |
210,185
-28,470
| -12% | -$694K | 0.03% | 379 |
|
|
2022
Q4 | $7.53M | Buy |
238,655
+87,413
| +58% | +$2.76M | 0.06% | 279 |
|
|
2022
Q3 | $4.27M | Buy |
151,242
+77,264
| +104% | +$2.18M | 0.05% | 364 |
|
|
2022
Q2 | $1.96M | Sell |
73,978
-39,021
| -35% | -$1.03M | 0.02% | 469 |
|
|
2022
Q1 | $3.96M | Sell |
112,999
-22,198
| -16% | -$777K | 0.02% | 433 |
|
|
2021
Q4 | $4.38M | Buy |
135,197
+53,303
| +65% | +$1.73M | 0.02% | 434 |
|
|
2021
Q3 | $2.42M | Buy |
81,894
+40,059
| +96% | +$1.18M | 0.02% | 582 |
|
|
2021
Q2 | $1.07M | Sell |
41,835
-19,750
| -32% | -$506K | 0.01% | 865 |
|
|
2021
Q1 | $846K | Buy |
+61,585
| New | +$846K | 0.01% | 813 |
|